NYSE:LCI (USA) Also trade in: Germany

Lannett Co Inc

$ 7.15 -0.04 (-0.56%)
On watch
Volume: 758,567 Avg Vol (1m): 1,394,319
Market Cap $: 280.91 Mil Enterprise Value $: 930.59 Mil
P/E (TTM): 0.00 P/B: 0.85
Earnings Power Value 31.93
Net Current Asset Value -10.14
Tangible Book -2.12
Projected FCF 37.1
Median P/S Value 23.07
Graham Number 0
Peter Lynch Value 18.75
DCF (FCF Based) 0
DCF (Earnings Based) 0
YTD (-%)

Financial Strength : 4/10

Current vs industry vs history
Cash-to-Debt 0.20
Equity-to-Asset 0.25
Debt-to-Equity 2.49
Debt-to-EBITDA -3.94
Interest Coverage 1.76
Piotroski F-Score 4
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 0.39
DISTRESS
GREY
SAFE
Beneish M-Score -2.44
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 10.09%
WACC 3.36%

Profitability & Growth : 8/10

Current vs industry vs history
Operating Margin % 22.11
Net Margin % -39.44
ROE % -56.16
ROA % -18.47
ROC (Joel Greenblatt) % -53.84
3-Year Total Revenue Growth Rate 18.90
3-Year Total EBITDA Growth Rate -6.30
3-Year EPS w/o NRI Growth Rate -43.00
N/A

» LCI's 30-Y Financials

Financials (Next Earnings Date: 2019-05-07)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NYSE:LCI

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS : 325412    SIC : 2834
Compare CAI:PHAR SHSE:603168 XKRX:092040 XKRX:086450 XKRX:271980 XKRX:229500 BOM:530549 TSXV:THCX SZSE:002728 TSX:CMED TSE:3151 LSE:APH SZSE:000790 SZSE:300702 SZSE:300436 XKRX:222040 SZSE:002923 NAS:RIGL SZSE:300519 SZSE:002750
Traded in other countries LN5.Germany
Address 9000 State Road, Philadelphia, PA, USA, 19136
Lannett Co Inc develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products in the United States. It offers solid oral, extended release, topical, nasal, and oral solution finished dosage forms of drugs that address a range of therapeutic areas, as well as ophthalmic, patch, foam, buccal, sublingual, soft gel, and injectable dosages. It also provides its products for various medical indications comprising glaucoma, Gastrointestinal, Migraine, Obesity, and Respiratory.

Ratios

Current vs industry vs history
Forward PE Ratio 7.19
N/A
PB Ratio 0.85
PS Ratio 0.40
Price-to-Free-Cash-Flow 3.41
Price-to-Operating-Cash-Flow 1.98
EV-to-EBIT -3.52
EV-to-EBITDA -4.52
EV-to-Revenue 1.34
Shiller PE Ratio 41.24
Current Ratio 2.44
Quick Ratio 1.88
Days Inventory 117.16
Days Sales Outstanding 144.81
Days Payable 50.90

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -1.00

Valuation & Return

Current vs industry vs history
Price-to-Projected-FCF 0.19
Price-to-Median-PS-Value 0.31
Price-to-Peter-Lynch-Fair-Value 0.38
Earnings Yield (Joel Greenblatt) % -28.24
Forward Rate of Return (Yacktman) % 48.77

More Statistics

Revenue (TTM) (Mil) $ 694.07
EPS (TTM) $ -7.3
Beta 2.97
Volatility % 113.98
52-Week Range $ 3.33 - 17.15
Shares Outstanding (Mil) 39.29

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 4
Positive ROA N
Positive CFROA Y
Higher ROA yoy N
CFROA > ROA Y
Lower Leverage yoy N
Higher Current Ratio yoy Y
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy Y